1. Home
  2. ZURA vs KOPN Comparison

ZURA vs KOPN Comparison

Compare ZURA & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.12

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$3.90

Market Cap

396.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
KOPN
Founded
2022
1984
Country
United States
United States
Employees
40
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
396.8M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
ZURA
KOPN
Price
$5.12
$3.90
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$13.00
$4.69
AVG Volume (30 Days)
1.7M
7.0M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
103.03
EPS
N/A
N/A
Revenue
N/A
$1,530,311.00
Revenue This Year
N/A
$50.07
Revenue Next Year
N/A
$33.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
46.53
52 Week Low
$1.26
$1.62
52 Week High
$7.25
$6.61

Technical Indicators

Market Signals
Indicator
ZURA
KOPN
Relative Strength Index (RSI) 59.46 40.13
Support Level $4.22 $3.64
Resistance Level $5.82 $4.16
Average True Range (ATR) 0.46 0.41
MACD 0.20 -0.09
Stochastic Oscillator 66.40 14.29

Price Performance

Historical Comparison
ZURA
KOPN

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: